Skip to main content
Log in

Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors

  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract.

Objective and design: To demonstrate the role of bile acids in immune modulation we examined the ability of select bile acids to inhibit leukocyte migration and chemoattractant receptor function.¶Materials: To elucidate this mechanism, we employed primary human monocytes, neutrophils and cell lines transfected to express either the high affinity fMLP receptor (FPR) or the low affinity fMLP receptor like 1 (FPRL1).¶Treatment: Cells were treated with chenodeoxycholic acid (CDCA) and related bile acids in a 0-400 micromolar range.¶Method: Cell viability, chemotaxis and calcium flux analysis were preformed.¶Results: We observed that pathophysiological levels (≤150 micromolar) of CDCA competitively inhibited 3H-fMLP binding to human monocytes, FPR and FPRL1 transfected cells. Additionally, CDCA reduced both the chemotactic and calcium flux responses induced by fMLP or "W" peptide. Further, CDCA inhibited anti-FPR anti body binding to monocytes.¶Conclusions: CDCA selectively inhibited human leukocyte chemotaxis and calcium flux induced by fMLP, but not other chemoattractants, suggesting a mechanism for inhibition of inflammation and suppression of innate immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received 22 June 2000; returned for revision 12 July 2000; accepted by G. Letts 11 August 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, X., Yang, D., Shen, W. et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm. res. 49, 744–755 (2000). https://doi.org/10.1007/s000110050656

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s000110050656

Navigation